Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Well-funded life sciences firms are making long-term progress – and their investors are too

This is an exciting time for British biotech and pharma, as the intense efforts to find a solution to COVID-19 offer a way out of the pandemic

- PMLiVE

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

The drug is recommended for use in adult patients who are already receiving statin treatment

- PMLiVE

Q&A: Louise Sharp

PME interviews Makara Health's owner and managing director

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial

Vaccine was 57% effective against South African strain

- PMLiVE

Keeping up with the developing regulatory requirements for gene and cell therapies

By Clive Glover

- PMLiVE

Kat Arnull joins Golin London as UK group chief strategy officer

Prior to joining Golin, Arnull worked at global communications agency Freuds

- PMLiVE

EU may restrict exports of some COVID-19 vaccines

Proposed strategy follows a confrontation between the EU and AstraZeneca

Creating strong commercial relationships in a COVID world

By Lisa Alderson

- PMLiVE

The UK reasserts that the AZ vaccine is ‘effective across all age groups’

Germany's draft guidance does not recommend the vaccine for people over 65

Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world

The importance of thinking differently, embracing risk, challenging conventional norms and trying new approaches

- PMLiVE

UK trial of Novavax COVID-19 vaccine demonstrates 89.3% efficacy

Vaccine demonstrated 60% efficacy in South Africa study

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links